5月20日，宜明昂科-B早盘上涨10.55%，报7.65港元。公司宣布其泰泽苏拜单抗联合奥希替尼的临床试验申请获批。此外，因与Axion Bio合作推进顺利，公司再获500万美元付款，累计收款达2000万美元。此次资金将助力非小细胞肺癌相关药物研发。免责声明：本文内容由开放的智能模型自动生成，仅供参考。
Source Link5月20日，宜明昂科-B早盘上涨10.55%，报7.65港元。公司宣布其泰泽苏拜单抗联合奥希替尼的临床试验申请获批。此外，因与Axion Bio合作推进顺利，公司再获500万美元付款，累计收款达2000万美元。此次资金将助力非小细胞肺癌相关药物研发。免责声明：本文内容由开放的智能模型自动生成，仅供参考。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.